Travel Alert Profile.Com
Travel News.
Vaccine Info.
GID & TMC Staff.
Pre-Exam Form.
Group Rates.
Important Links.
Map To Office.
Home Page.

Travel News.

When Traveling Abroad...

(Released October 11, 2000; updated October 27, 2000)
The information contained in this article was obtained
from the Centers for Disease Control

Malarone is a new antimalarial drug approved in the United States in July 2000 for both treatment and prophylaxis of malaria.


Malarone has been shown to be highly efficacious in the treatment of uncomplicated malaria caused by Plasmodium falciparum, including malaria that has been acquired in areas with chloroquine resistant or multi-drug resistant strains. Malarone is available in adult and pediatric strength forms. The daily dose should be taken at the same time each day with food or milk.


Malarone has shown good prophylactic efficacy for prevention of P. falciparum malaria, including those infections acquired in areas with chloroquine resistant strains. Malarone is now one of three options (the others are mefloquine or doxycycline) for prevention of malaria when traveling to areas with chloroquine resistant P. falciparum malaria.

The adult dosing regimen for prophylaxis with Malarone is one adult table daily starting one to two days prior to travel, taken daily during travel and continuing daily for seven days after leaving the malarious area. The pediatric dosing regimen for prophylaxis (which also starts one to two days before travel and continues during travel and for seven days after leaving the malarious area) is based on weight.


The most common adverse effects reported in people using Malarone for prophylaxis or treatment was abdominal pain, nausea, vomiting and headache.


There are insufficient data regarding the use of Malarone during pregnancy and breast-feeding for either treatment or prophylaxis. Therefore, Malarone is not currently recommended for pregnant women unless the potential benefit outweighs the potential risk to the fetus.

It is not known whether Malarone is excreted into human milk. Based on the experience with other antimalarial drugs, the quantity of drug transferred in breast milk is insufficient to provide adequate protection against malaria for an infant. Because data are not yet available on the safety and efficacy of Malarone in children weighing less than 11 kg, it should not be given to a woman who breast-feeds an infant who weighs less than 11 kg unless the potential benefit to the woman outweighs the potential risk to the infant.

For further questions related to the use of Malarone, the Centers for Disease Control may be contacted through the Malaria Hotline at 888-232-3228. Travelers should consult a physician prior to travel.

Office hours are Monday through Friday:
9:00 a.m. until 12:00 noon and 2:00 p.m. until 5:00 p.m.
We accept cash, check, Visa and Mastercard.

C. Michael Lewis, D.O.
G-8195 S. South Saginaw Street
Suite B
Grand Blanc, MI 48439

Phone: (810) 694-5393
Toll Free: 800-966-5393
Fax: (810) 694-5394

Medical Evaluation.
Vaccine Information.
Travel Precautions.
Emergency Contacts.

Search this web site.

Select a topic below